Enamine, FCH Group Collaborate
News Oct 24, 2016
Enamine Ltd. announced that it has signed a collaboration agreement with small molecule design house FCH Group Ltd (FCH). Under the terms of the agreement, Enamine will supply FCH with non-exclusive reagents, intermediates and chemical building blocks from its extensive library, to support FCH’s innovative synthesis programs. In return, FCH will grant Enamine a share in net sales of the excess amounts of the synthesized compounds. Both companies will market and sell the new products under this collaboration in their respective compound library catalogues.
FCH has been working with Enamine for two years to design synthetically feasible screening libraries and building blocks. FCH’s original library focuses on small molecular weight polar compounds with lead-like properties. It has been mutually acknowledged that Enamine’s inventory provides a rich pool of medchem building blocks, whose unique properties and pharmacophore features are of great value for FCH library design. Convenient access to over 120,000 building blocks and reagents at Enamine will allow FCH to significantly speed up production of compound libraries and building blocks.
“Synthesis of our cutting-edge screening libraries with enhanced lead-like profiles requires usage of novel advanced building blocks,” said Dr Yurii Moroz, CSO at FCH. He continued: “We are grateful to Enamine for their support and are pleased to have established this type of collaboration with them in the area of tangible arrays. We have seen a great synergy with Enamine’s REAdily accessibLe (REAL) concept. Their building blocks provide a very good match to our design strategy, enabling us to synthesize quality diverse compound libraries and unusual building blocks within a short time.”
Michael Bossert, Head of Strategic Alliances at Enamine, commented: “It is important to make our large stock of building blocks available to the drug discovery industry for open innovation, and this agreement with FCH exemplifies this strategy. We are keen to expand this collaboration model to other well-established science-driven players. In this way, capitalizing on our broad network of users, we are accelerating delivery of new innovative molecules to the global drug discovery industry.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE